aCentre for Global Health Research, Brighton and Sussex Med School, United Kingdom;
bDepartment of Nuclear Medicine, Brighton and Sussex University Hospitals, United Kingdom;
cDepartment of Nuclear Medicine, University of Leipzig, Germany;
dDepartment of Infectious Diseases, University of Gothenburg, Sweden;
eDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Sweden;
fClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Sweden;
gDepartment of Neuropsychology, Brighton and Sussex University Hospitals, United Kingdom; and
hFaculty of Health, University of Plymouth, United Kingdom.
Correspondence to: Jaime H. Vera, MD, PhD, MRCP, Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom BN1 9PX (e-mail: [email protected]).
Supported by an Association of Physicians of Great Britain Young Investigator Award, and a Piramal Imaging LtD (now Life Molecular Imaging Ltd) Investigator Award Grant to J.H.V.
J.H.V. has received travel and research grants from and has been speaker/advisor for Merck, Janssen Cilag, Piramal Imaging, ViiV Healthcare, and Gilead sciences. M.G. has received research grants from and has been speaker/advisor for Merck, Janssen Cilag, Biogen, Amgen, Novo Nordic, ViiV Healthcare, and Gilead Sciences. K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The remaining authors have no conflicts to report.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
